Literature DB >> 15619632

Inhibition of respiratory viruses by nasally administered siRNA.

Vira Bitko1, Alla Musiyenko, Olena Shulyayeva, Sailen Barik.   

Abstract

Respiratory syncytial virus (RSV) and parainfluenza virus (PIV) are two respiratory pathogens of paramount medical significance that exert high mortality. At present, there is no reliable vaccine or antiviral drug against either virus. Using an RNA interference (RNAi) approach, we show that individual as well as joint infection by RSV and PIV can be specifically prevented and inhibited by short interfering RNAs (siRNAs), instilled intranasally in the mouse, with or without transfection reagents. The degree of protection matched the antiviral activity of the siRNA in cell culture, allowing an avenue for quick screening of an efficacious siRNA. When targeting both viruses in a joint infection, excess of one siRNA moderated the inhibitory effect of the other, suggesting competition for the RNAi machinery. Our results suggest that, if properly designed, low dosages of inhaled siRNA might offer a fast, potent and easily administrable antiviral regimen against respiratory viral diseases in humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15619632     DOI: 10.1038/nm1164

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  239 in total

1.  Competition between small RNAs: a quantitative view.

Authors:  Adiel Loinger; Yael Shemla; Itamar Simon; Hanah Margalit; Ofer Biham
Journal:  Biophys J       Date:  2012-04-18       Impact factor: 4.033

Review 2.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

3.  Double-stranded RNA induces sequence-specific antiviral silencing in addition to nonspecific immunity in a marine shrimp: convergence of RNA interference and innate immunity in the invertebrate antiviral response?

Authors:  Javier Robalino; Thomas Bartlett; Eleanor Shepard; Sarah Prior; Guillermo Jaramillo; Edward Scura; Robert W Chapman; Paul S Gross; Craig L Browdy; Gregory W Warr
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

Review 4.  Silence of the transcripts: RNA interference in medicine.

Authors:  Sailen Barik
Journal:  J Mol Med (Berl)       Date:  2005-07-19       Impact factor: 4.599

5.  Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA).

Authors:  Michael J Wagner; Rahul Mitra; Mark J McArthur; Wallace Baze; Kirstin Barnhart; Sherry Y Wu; Cristian Rodriguez-Aguayo; Xinna Zhang; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2017-03-06       Impact factor: 6.261

6.  RNA interference of STAT6 rapidly attenuates ongoing interleukin-13-mediated events in lung epithelial cells.

Authors:  William Walker; Gareth D Healey; Julian M Hopkin
Journal:  Immunology       Date:  2008-10-29       Impact factor: 7.397

7.  RNA interference as a potential therapeutic treatment for inflammation associated lung injury.

Authors:  Joanne Lomas-Neira; Chun-Shiang Chung; Alfred Ayala
Journal:  Int J Clin Exp Med       Date:  2008-02-25

8.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

9.  Role of human beta-defensin-2 during tumor necrosis factor-alpha/NF-kappaB-mediated innate antiviral response against human respiratory syncytial virus.

Authors:  Srikanth Kota; Ahmed Sabbah; Te Hung Chang; Rosalinda Harnack; Yan Xiang; Xiangzhi Meng; Santanu Bose
Journal:  J Biol Chem       Date:  2008-06-20       Impact factor: 5.157

10.  Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.

Authors:  Mari Numata; Hong Wei Chu; Azzeddine Dakhama; Dennis R Voelker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.